今日焦点！上海南汇新城推进特斯拉FSD落地试点：无人驾驶机场专线出租车指日可待

上海南汇新城推进特斯拉FSD落地试点：无人驾驶机场专线出租车指日可待

上海，2024年6月18日 - 随着科技的飞速发展，自动驾驶技术日趋成熟，并逐步走向商业化应用。近日，上海南汇新城传来喜讯：特斯拉FSD（完全自动驾驶）技术将在该区域落地试点，并有望推出无人驾驶机场专线出租车服务。

政策利好，特斯拉FSD试点加速落地

上海南汇新城一直以来都高度重视科技创新和智能交通建设。今年，南汇新城被列为上海市人工智能产业发展示范区，为自动驾驶技术的落地应用提供了良好的政策环境。

据悉，特斯拉FSD试点项目将首先在南汇新城的指定区域内开展，包括滴水湖核心区、金融街、空港新城等。特斯拉将在这些区域内铺设自动驾驶专用道路，并配备相应的安全设施。

无人驾驶机场专线出租车，出行新体验

无人驾驶机场专线出租车是特斯拉FSD试点项目的重要组成部分。该项目旨在为南汇新城的乘客提供安全、便捷、舒适的出行体验。

无人驾驶机场专线出租车将采用特斯拉Model 3车型，搭载特斯拉最新的FSD自动驾驶系统。该系统可以实现自主导航、自动泊车、自动变道等功能，并能够应对复杂的交通状况。

打造智慧交通新标杆

特斯拉FSD试点的落地，将为上海南汇新城的交通发展注入新的活力。南汇新城也将以此为契机，进一步推进智慧交通建设，打造更加安全、便捷、高效的交通体系。

专家观点：

上海交通大学交通运输学院教授、自动驾驶技术专家王教授表示，特斯拉FSD试点的落地，是上海自动驾驶产业发展的重要里程碑。该项目将为自动驾驶技术的商业化应用积累宝贵经验，并有望推动自动驾驶产业的快速发展。

相信在不久的将来，无人驾驶汽车将成为我们日常生活中的常见交通工具，为我们的出行带来更加便利、舒适的体验。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.